promethazine Side Effects
Also known as: Phenergan
Analysis of 17,969 adverse event reports submitted to the FDA from 1996 to 2025.
Total Reports
17,969
Death-Related
1,754
9.8% of reports
Hospitalizations
7,143
39.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,754 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 521 |
| NAUSEA | 213 |
| TOXICITY TO VARIOUS AGENTS | 204 |
| VOMITING | 172 |
| PNEUMONIA | 152 |
| FATIGUE | 140 |
| DYSPNOEA | 135 |
| ASTHENIA | 120 |
| CARDIAC ARREST | 116 |
| DIARRHOEA | 113 |
| SEPSIS | 112 |
| RENAL FAILURE | 111 |
| PAIN | 110 |
| OFF LABEL USE | 109 |
| HYPOTENSION | 106 |
| RESPIRATORY FAILURE | 94 |
| ANAEMIA | 91 |
| ABDOMINAL PAIN | 90 |
| PYREXIA | 85 |
| DECREASED APPETITE | 81 |
Reactions in Hospitalization Reports
Top reactions in 7,143 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| NAUSEA | 1,057 |
| VOMITING | 903 |
| PAIN | 777 |
| DIARRHOEA | 615 |
| PNEUMONIA | 608 |
| DYSPNOEA | 602 |
| FATIGUE | 576 |
| ABDOMINAL PAIN | 506 |
| HEADACHE | 486 |
| PYREXIA | 484 |
| ANXIETY | 458 |
| DEHYDRATION | 451 |
| ASTHENIA | 442 |
| FALL | 379 |
| WEIGHT DECREASED | 355 |
| ANAEMIA | 350 |
| CHEST PAIN | 349 |
| DIZZINESS | 343 |
| URINARY TRACT INFECTION | 331 |
| MALAISE | 316 |
Nearby — Related Medications
What the FAERS Data Reveals About promethazine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 17,969 voluntary reports linked to promethazine and its brand equivalents (Phenergan), spanning 1996 through 2025. Of those, 1,754 (9.8%) listed death as an outcome and 7,143 (39.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 75% were female and 25% male; age distribution skews toward 45-64, with 5,108 reports in that bracket. The single most reported reaction is nausea with 2,530 submissions, followed by vomiting and pain.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.